There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gritstone Oncology Inc (GRTS), G1 Therapeutics Inc (GTHX) and Vertex Pharmaceuticals (VRTX) with bullish sentiments.
Gritstone Oncology Inc (GRTS)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright initiated coverage with a Buy rating on Gritstone Oncology Inc and a price target of $17. The company’s shares closed yesterday at $11.64, close to its 52-week low of $10.89.
Ramakanth said:
“We are initiating coverage of 12- month price target of $17.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected GRANITE-001 and SLATE-001 revenues through 2030, assuming a 12.5% discount rate and 3% terminal growth rate.”
According to TipRanks.com, Ramakanth has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.6% and a 33.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Collplant Holdings Ltd, Leap Therapeutics Inc, and Tyme Technologies Inc.
Currently, the analyst consensus on Gritstone Oncology Inc is a Moderate Buy with an average price target of $31.
See today’s analyst top recommended stocks >>
G1 Therapeutics Inc (GTHX)
In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on G1 Therapeutics Inc, with a price target of $72. The company’s shares closed yesterday at $17.31, close to its 52-week low of $15.21.
White wrote:
“We base our $72 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC. We use the net present value of our revenue forecast through 2026, apply a 50% and 40% POS for trilaciclib and lerociclib, respectively, a 3x price/sales multiple, and a $2.40/share value for the early stage pipeline that includes trilaciclib and lerociclib in other indications, and G1T48.”
According to TipRanks.com, White is a 5-star analyst with an average return of 12.1% and a 46.6% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for G1 Therapeutics Inc with a $58.50 average price target, representing a 238.0% upside. In a report issued on March 1, Cowen & Co. also maintained a Buy rating on the stock.
Vertex Pharmaceuticals (VRTX)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals today and set a price target of $220. The company’s shares closed yesterday at $181.11.
Fein said:
“Valuation and risks to our investment thesis. Our price target of $220/share, is based on an equally weighted composite of: (a) $216/share, as a 30x multiple of taxed and diluted FY26 GAAP EPS of $22.92 discounted back to and (b) an NPV of $223/share (discount rate 11.0%, terminal growth rate of 2.0%).”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.3% and a 47.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $215.92, implying a 19.2% upside from current levels. In a report issued on February 25, Oppenheimer also assigned a Buy rating to the stock with a $200 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
